ATE247958T1 - Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind - Google Patents

Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind

Info

Publication number
ATE247958T1
ATE247958T1 AT94909686T AT94909686T ATE247958T1 AT E247958 T1 ATE247958 T1 AT E247958T1 AT 94909686 T AT94909686 T AT 94909686T AT 94909686 T AT94909686 T AT 94909686T AT E247958 T1 ATE247958 T1 AT E247958T1
Authority
AT
Austria
Prior art keywords
neovascularization
imidazole
treat diseases
diseases characterized
imidazoles
Prior art date
Application number
AT94909686T
Other languages
English (en)
Inventor
Jose Halperin
Carlo Brugnara
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of ATE247958T1 publication Critical patent/ATE247958T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94909686T 1993-02-18 1994-02-18 Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind ATE247958T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/018,840 US5512591A (en) 1993-02-18 1993-02-18 Treatments for diseases characterized by neovascularization
PCT/US1994/001740 WO1994018967A1 (en) 1993-02-18 1994-02-18 Treatments for diseases characterized by neovascularization

Publications (1)

Publication Number Publication Date
ATE247958T1 true ATE247958T1 (de) 2003-09-15

Family

ID=21790036

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909686T ATE247958T1 (de) 1993-02-18 1994-02-18 Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind

Country Status (8)

Country Link
US (3) US5512591A (de)
EP (1) EP0644760B1 (de)
JP (1) JPH08506594A (de)
AT (1) ATE247958T1 (de)
AU (1) AU6243494A (de)
CA (1) CA2118313A1 (de)
DE (1) DE69433079T2 (de)
WO (1) WO1994018967A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
US6051573A (en) * 1994-06-28 2000-04-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists
GB2293323A (en) * 1994-09-12 1996-03-27 Orion Yhtymae Oy Antibiotics and bismuth salts for treating bacterial infections
EP0783303B1 (de) * 1994-09-16 2002-11-27 President And Fellows Of Harvard College Verwendung von aromatischen halogenverbindungen zur behandlung der zellproliferation in säugetieren
AU732881C (en) 1994-09-16 2002-11-07 Children's Medical Center Corporation Triaryl and diaryl compounds, their analogues and uses thereof
US5556871A (en) * 1995-04-24 1996-09-17 President & Fellows Of Harvard College Method for treating epithelial precancerous lesions with topical inidazoles
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
KR19990082523A (ko) 1996-02-15 1999-11-25 간자와 무츠와 혈관생성 억제제
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
US6057122A (en) 1996-05-03 2000-05-02 Abbott Laboratories Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
US6699838B1 (en) 1996-05-03 2004-03-02 Abbott Laboratories Antiangiogenic peptides
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
SK22499A3 (en) * 1996-08-23 1999-10-08 Cook Biotech Inc Graft prosthesis, materials and methods
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
EP1012163A4 (de) * 1997-07-11 2003-01-29 Cv Technologies Inc Formulierung, ausgehend von haifischknorpel, zur behandl.ung von erkrankungen, die mit erhöhtem phf oder erhöhtem intrazellulären kalzium einhergehen
US6121299A (en) * 1998-03-30 2000-09-19 Lovelace Respiratory Research Institute Modulating inflammation with cytochrome P-450 activators and inhibitors
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US20040022788A1 (en) 1998-05-19 2004-02-05 Moser Tammy L. Compositions and methods for promoting or inhibiting angiogenesis
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
WO2000069439A1 (en) * 1999-05-12 2000-11-23 Neurosearch A/S Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
WO2002040018A1 (en) * 2000-11-14 2002-05-23 Alcon, Inc. Treatment of glaucoma and ocular hypertension
US20040077575A1 (en) * 2002-01-11 2004-04-22 Giordano Giovan Giacomo Inhibition of pathological angiogenesis in vivo
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20030050246A1 (en) * 2001-07-26 2003-03-13 Fortuna Haviv Peptides having antiangiogenic activity
US20030045477A1 (en) * 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
WO2003018014A2 (en) * 2001-08-23 2003-03-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of inhibiting formation of vascular channels and profileration using pyridinone derivatives
AU2003259028A1 (en) * 2002-06-10 2003-12-22 Combinatorx, Incorporated Combinations for the treatment of rheumatoid arthritis
KR100478671B1 (ko) * 2002-07-15 2005-03-22 사회복지법인 삼성생명공익재단 클로트리마졸을 포함하는 혈관 재협착 예방 및 치료용약학 조성물, 및 스텐트
EP1606305A4 (de) * 2003-03-12 2009-06-24 Vasgene Therapeutics Inc Nukleinsäureverbindungen für die inhibierung von angiogenese und tumorwachstum
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1667632A4 (de) * 2003-09-18 2009-07-01 Childrens Medical Center Behandlung von schwerer distaler colitis
JP2007511522A (ja) * 2003-11-14 2007-05-10 エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド 血管新生およびがん細胞増殖の調節方法
CN101072797B (zh) * 2004-03-12 2012-05-09 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
DK1730196T3 (da) 2004-03-12 2011-03-28 Vasgene Therapeutics Inc EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst
EP1737452A1 (de) 2004-04-06 2007-01-03 Angiogenetics Sweden AB Verbindungen zur beeinflussung der angiogenese und anwendungsverfahren
US20070142433A1 (en) * 2004-04-06 2007-06-21 Helmut Augustin Angiogenesis-affecting compounds and methods of use thereof
US20070142308A1 (en) * 2005-04-06 2007-06-21 Helmut Augustin Angiogenesis-affecting compounds and methods for use thereof
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
CA2581423A1 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
US20070218061A1 (en) * 2005-09-23 2007-09-20 Vasgene Therapeutics, Inc. Use of ephrinb2 directed agents for the treatment or prevention of viral infections
US7889640B2 (en) * 2006-10-16 2011-02-15 Fujitsu Limited System and method for establishing protected connections
CA2696164C (en) * 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678030A (en) * 1970-02-27 1972-07-18 Ajinomoto Kk Imidazole derivatives inhibiting nf sarcoma
US3901908A (en) * 1970-12-28 1975-08-26 Ciba Geigy Corp 2-alkyl- and 2-cycloalkyl-4,5-bis-phenyl-imidazoles
US3965112A (en) * 1971-01-11 1976-06-22 John Wyeth & Brother Limited Imidazoline derivatives
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
JPS6048486B2 (ja) * 1976-01-01 1985-10-28 木場 常義 抗リウマチ剤
US4119723A (en) * 1977-07-08 1978-10-10 John R. A. Simoons Treatment of rheumatoid arthritis and related diseases
US4218449A (en) * 1978-08-21 1980-08-19 John R. A. Simoons Treatment of rheumatoid arthritis and related diseases
US4491588A (en) * 1982-03-31 1985-01-01 University Of Tennessee Research Corporation Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics
US4942162A (en) * 1982-03-31 1990-07-17 University Of Tennessee Research Corporation Topical treatment of seborrheic dermatitis with ketoconazole
US4657925A (en) * 1984-08-13 1987-04-14 Nelson Research & Development Co. Method and compositions for reducing the intraocular pressure of mammals
US4569935A (en) * 1983-03-17 1986-02-11 University Of Tennessee Research Corp. Topical treatment of psoriasis with imidazole antibiotics
US4863941A (en) * 1985-06-18 1989-09-05 Hoffmann-La Roche Inc. Glycerol derivatives
US4758580A (en) * 1985-06-26 1988-07-19 Yamanouchi Pharmaceutical Co., Ltd. Inhibiting growth of tumors with certain substituted phenoxy dimethyl alkanoic acids, esters or salts
US4916118A (en) * 1986-08-18 1990-04-10 Board Of Regents, The University Of Texas System Pharmaceutical administration systems containing chemotactic peptides
US5326790A (en) * 1986-11-19 1994-07-05 Dermatologic Research Corporation Administration of skin medications by use of dicarboxylic acids and derivatives
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US4837333A (en) * 1987-05-14 1989-06-06 G. D. Searle & Co. Substituted alkylidene imidazoles
US5023090A (en) * 1989-08-16 1991-06-11 Levin Robert H Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE
CA1317588C (en) * 1988-02-29 1993-05-11 Tohru Ueda Imidazole derivatives, process for production thereof, and use thereof
FR2641278B1 (fr) * 1989-01-05 1991-03-22 Lipha Piperidines, procedes de preparation et medicaments les contenant
US5132315A (en) * 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound
EP0525123B1 (de) * 1990-06-20 1997-09-17 PHARMACIA & UPJOHN COMPANY Antiatherosklerotische und antithrombotische 1-benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on-derivate
BE1004029A6 (nl) * 1990-11-22 1992-09-08 Mol Omer De Farmaceutische samenstelling en farmaceutische set voor het behandelen van kanker.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5273992A (en) * 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
GB2273873A (en) * 1992-12-23 1994-07-06 Univ Sheffield Treatment of psoriasis
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization

Also Published As

Publication number Publication date
DE69433079D1 (de) 2003-10-02
WO1994018967A1 (en) 1994-09-01
US5643936A (en) 1997-07-01
DE69433079T2 (de) 2004-06-17
CA2118313A1 (en) 1994-09-01
AU6243494A (en) 1994-09-14
EP0644760A4 (de) 1996-03-13
EP0644760B1 (de) 2003-08-27
EP0644760A1 (de) 1995-03-29
US5591763A (en) 1997-01-07
US5512591A (en) 1996-04-30
JPH08506594A (ja) 1996-07-16

Similar Documents

Publication Publication Date Title
ATE247958T1 (de) Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind
ATE192045T1 (de) Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose
DE69424732D1 (de) Verwendung eines imidazols zur herstellung eines medikamentes zur behandlung der arteriosklerose
ATE454141T1 (de) Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten
GR3021364T3 (en) Composition and method of enhancing sun tanning.
DE69334035D1 (de) Verfahren zur vorbeugung von nmda-rezeptor vermittelten neuronalen schäden
ATE202701T1 (de) Behandlung und prophylaxe von durch parasiten oder bakterien verursachten erkrankungen
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
HUP9800729A2 (hu) Arteriovénás és graft kezelések: módszerek és készítmények
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
DE69902154D1 (de) Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung.
NO970161L (no) Triazolforbindelser og anvendelse derav
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE69333413D1 (de) 5-ht2-antagonisten in der behandlung venöser zustände
DE69718469D1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
DE69007486D1 (de) Verwendung von calciumantagonisten für die behandlung von narben.
ATE179594T1 (de) Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
ATE141053T1 (de) Verwendung von torasemid zur behandlung von hirnödemen
ATE330604T1 (de) Behandlung von manischen erkrankungen
DE69218200D1 (de) Behandlung von leberkrebs
ATE239497T1 (de) Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen
EP0612527A3 (de) Verwendung von Rhamnan, Rhamnose oder Rhamnoseoligomeren zur Behandlung des Magengeschwürs.
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties